Opinion

Video

Case 4: Metastatic Castration-Resistant Prostate Cancer With an HRR Alteration

Panelists discuss how the management of metastatic castration-resistant prostate cancer with a homologous recombination repair (HRR) alteration involves targeted therapies, such as PARP inhibitors, to exploit the genetic vulnerability and improve treatment response.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related Videos
Related Content
© 2025 MJH Life Sciences

All rights reserved.